- Global Pharma News & Resources

PHASTAR Attendance at BIO Japan and DIA Japan Supports Move into Asia

Durham, NC and London, UK – October 7, 2019  – PHASTAR, a global CRO, will be exhibiting at BIO Japan from October 9-11 at the Pacific Convention Center in Yokohama and also at DIA Japan from November 9-11 at Tokyo Big Sight, Tokyo. These commitments underscore the company’s growing presence in the Asian market as well as its support for existing and potential new customers in the area.

“PHASTAR is in the final stages of establishing our office in Tokyo, which we hope to announce in the first quarter 2020,” said Kevin Kane, CEO and Founder of PHASTAR. “Japan is a dynamic market for the life sciences.  Establishment of our presence there will bring the full functionality of PHASTAR’s portfolio of statistical consulting, programming and reporting skills, data management services and innovative AI and machine learning capabilities to companies developing new drugs and medical devices.” 

According to reports from its government, Japan is currently the world’s second largest pharmaceuticals market behind the U.S. and China and is expected to grow annually. Japan has also announced that it is easing several life science regulations and accelerating approval of innovative new drugs in a campaign to promote investment by both domestic and foreign pharma companies.

With its presence both at BIO Japan and DIA Japan, PHASTAR will be able to showcase opportunities to support the development of new drugs and devices by providing expert consultants and managing and delivering in-house project, FSP-style arrangements and preferred partnerships. 


PHASTAR is a global CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP style arrangements and preferred partnerships. PHASTAR currently has over 250 staff across 10 offices (United States, United Kingdom, Australia, Germany and Kenya) with plans to open additional locations in Asia and the West Coast of the United States to serve prospective and existing clients. PHASTAR’s number one priority is to ensure that the work we produce is of the highest quality. Every project PHASTAR undertakes utilizes our unique internal processes which are designed to ensure optimal quality.  All PHASTAR’s statistical, programming, data management and data science staff are trained in the “PHASTAR Discipline” - our in-house approach to data analysis and collection. This comprises a set of common sense (but commonly ignored) principles that, if followed, guarantee error free outcomes. The “PHASTAR Discipline” also includes a series of intranet-based checklists highlighting potential pitfalls and points-to-consider when conducting clinical trials, enabling over 2,500 years of combined technical knowledge to be shared across the company.  For further information on PHASTAR contact

Editor Details

  • Company:
  • Name:
Last Updated: 08-Oct-2019